EP4 Antagonist Crystal Forms for Reduced Side Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic agents for treating diseases associated with the EP4 receptor, such as arthritis and cancer, often have cardiovascular and gastrointestinal side effects, and there is a need for more effective and safer alternatives that can target the EP4 pathway specifically.
Innovation Solution
Development of a crystal form and pharmaceutically acceptable salts of a compound that effectively antagonizes the EP4 receptor, including free acid crystal forms and salts like tromethamine, diethylamine, and lysine salts, which provide improved stability, solubility, and reduced hygroscopicity, facilitating better drug delivery and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional NSAIDs or COX-2 inhibitors are used to treat arthritis and inflammatory diseases, then anti-inflammatory and analgesic effects are achieved, but cardiovascular and gastrointestinal side effects occur
Solution Approach 1:
The invention segments the broad COX enzyme inhibition mechanism into selective EP4 receptor antagonism. By designing compounds that specifically target the EP4 prostaglandin receptor rather than broadly inhibiting COX enzymes, the patent achieves anti-inflammatory and analgesic effects through a more selective pathway, thereby reducing the cardiovascular and gastrointestinal side effects associated with conventional NSAIDs and COX-2 inhibitors
Solution Approach 2:
The patent applies local quality by creating compounds with specific molecular structures (such as the pyrazole carboxamide core structure with specific substituents) that confer selective affinity for the EP4 receptor. This localized molecular design ensures that the therapeutic action is concentrated at the EP4 receptor site, preventing widespread enzymatic inhibition that causes systemic side effects
2Object-affected harmful factors
If selective EP4 antagonists are developed to reduce side effects, then cardiovascular safety is improved, but physicochemical stability and solubility may be compromised
Solution Approach 1:
The patent systematically varies molecular parameters including substituent groups on the pyrazole ring, chain length and composition of linkers, and functional groups on aromatic rings to optimize the balance between EP4 selectivity and physicochemical properties. By adjusting these parameters, the invention achieves compounds that maintain cardiovascular safety while improving stability and solubility characteristics
Solution Approach 2:
The patent employs composite molecular structures combining multiple functional moieties: a pyrazole carboxamide core, aromatic rings with specific substituents, and aliphatic linkers. This composite design allows different parts of the molecule to contribute to different properties - the core structure provides EP4 binding affinity while substituent groups modulate solubility and stability, achieving a balanced pharmaceutical profile
3Stability of the object's composition
If crystal forms and salts of the compound are developed, then solubility and stability are improved, but manufacturing complexity increases
Solution Approach 1:
The patent performs preliminary characterization of multiple crystal forms and salt compounds during the development phase, identifying forms with superior stability and solubility properties before scale-up. By pre-selecting the most promising crystal forms (such as specific polymorphs or solvates) and salt compositions, the invention simplifies subsequent manufacturing processes rather than requiring extensive optimization during production
Solution Approach 2:
The patent explores various salt forms that can be easily prepared and discarded during screening, using readily available counterions to generate diverse salt compounds for rapid evaluation. This approach allows efficient identification of stable, soluble forms without requiring complex or expensive materials, facilitating straightforward translation to manufacturing
Data Source
AI summary
An EP4 antagonist represented by formula I, which specifically comprises a crystal form thereof, a pharmaceutically acceptable salt or crystal form thereof, a preparation method therefor, a composition containing same, and a medical use of a related compound. The structure of formula I is shown below: